title: High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice.
authors.affiliation: Velindre Cancer Centre, Cardiff, UK.
authors.forename: J S
authors.initials: JS
authors.lastname: Tanguay
authors.affiliation: Cardiff University, Cardiff, UK.
authors.forename: C
authors.initials: C
authors.lastname: Catlow
authors.affiliation: Velindre Cancer Centre, Cardiff, UK.
authors.forename: C
authors.initials: C
authors.lastname: Smith
authors.affiliation: Velindre Cancer Centre, Cardiff, UK.
authors.forename: J
authors.initials: J
authors.lastname: Barber
authors.affiliation: Cardiff University, Cardiff, UK.
authors.forename: J
authors.initials: J
authors.lastname: Staffurth
authors.affiliation: Velindre Cancer Centre, Cardiff, UK.
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.affiliation: Velindre Cancer Centre, Cardiff, UK.
authors.forename: N
authors.initials: N
authors.lastname: Palaniappan
authors.affiliation: Velindre Cancer Centre, Cardiff, UK.
authors.forename: M
authors.initials: M
authors.lastname: Button
authors.affiliation: Cardiff University, Cardiff, UK.
authors.forename: M D
authors.initials: MD
authors.lastname: Mason
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009503:Neutropenia; D011471:Prostatic Neoplasms; D043823:Taxoids
chemical_list: D043823:Taxoids; D000077143:Docetaxel